Oral sermorelin: sublingual, nasal & injection compared. - Reddit

Why doesn’t oral sermorelin work?

The digestive system is extraordinarily effective at breaking down proteins and peptides into their component amino acids — which is exactly what it is designed to do. The same enzymatic machinery that digests dietary protein (proteases in the stomach, peptidases throughout the small intestine) degrades therapeutic peptides before they can be absorbed intact.

Sermorelin specifically:

• Is composed of 29 amino acids, the first 29 of human growth hormone-releasing hormone (GHRH).
• Its biological activity depends on maintaining the intact amino acid sequence, particularly at the N-terminus (amino acids 1–29 are required for biological activity; truncation at the N-terminus eliminates receptor binding).
• Enzymatic cleavage anywhere along this sequence generates fragments that do not activate the GHRH receptor and do not stimulate GH release.

True oral sermorelin — swallowed, absorbed through the GI tract — has not been demonstrated to produce meaningful pituitary GH secretion in human clinical research. This is not a theoretical concern; it reflects the practical pharmacokinetic reality of oral peptide administration.

Why is subcutaneous injection the evidence-anchored standard?

Subcutaneous injection is how sermorelin was studied in clinical trials and how it has been clinically used in licensed physician-supervised programs. Subcutaneous absorption delivers sermorelin intact into the systemic circulation via absorption from the subcutaneous compartment, bypassing GI degradation entirely.

The injection site is typically the abdomen, thigh, or upper arm. Subcutaneous injections of sermorelin use a short, fine-gauge needle — the process is substantially less involved than the intramuscular injections many people associate with hormone therapy.

The published research on sermorelin’s effect on pituitary GH secretion, IGF-1 levels, body composition parameters, and sleep architecture was conducted using subcutaneous administration. This is the evidence base that licensed clinicians draw on when they discuss expected outcomes with patients.

Does sublingual sermorelin work? Mechanism and evidence

Sublingual administration routes sermorelin under the tongue, where the mucosal tissue is thin and highly vascularized. Drug molecules absorbed sublingually enter the sublingual venous plexus and reach systemic circulation without passing through the GI tract or hepatic first-pass metabolism.

This is a legitimate pharmacokinetic rationale, and sublingual delivery works well for small molecules (notably nitroglycerine and some benzodiazepines). For peptides, the picture is more complex:

• The sublingual mucosa has peptidase activity of its own, though lower than the GI tract.
• Penetration of larger peptides across the sublingual epithelium is limited by molecular size.
• Clinical evidence specifically establishing bioavailability or GH-stimulating efficacy of sublingual sermorelin in humans is limited. Compounding pharmacies preparing sublingual troches do so based on pharmacokinetic rationale rather than a direct comparative clinical trial against injection.

Sublingual sermorelin may be a reasonable option for patients with needle aversion, but patients choosing it in lieu of injection should understand that the evidence supporting its bioavailability is less robust than for subcutaneous injection.

Is nasal sermorelin effective? Intranasal peptide delivery

Intranasal delivery routes peptides through the nasal mucosa. The nasal epithelium is more permeable than GI mucosa and absorbs certain peptides into systemic and direct central nervous system circulation. Early research on intranasal GHRH and GHRH-related peptides demonstrated pituitary responses, suggesting the route can, at least in some formulations and doses, deliver biologically active peptide.

However:

• Bioavailability of intranasal peptides is typically substantially lower than subcutaneous injection. The same dose delivered intranasally is unlikely to produce the same systemic concentration as the same dose injected subcutaneously.
• Formulation matters significantly for nasal delivery: particle size, absorption enhancers, nasal anatomical variation, and mucosal congestion all affect actual absorption on a given day.
• Specific comparative clinical data on nasal vs. subcutaneous sermorelin bioavailability and GH-stimulating efficacy has not been published in the peer-reviewed literature in a form that allows confident dose equivalency recommendations.

Nasal sermorelin is sometimes explored by clinicians for patients who prefer a needle-free route, but like sublingual, it comes with the caveat that the evidence base for efficacy is substantially thinner than subcutaneous injection.

How do clinicians choose between sermorelin formulations?

A responsible prescribing clinician considers several factors when selecting a sermorelin formulation for a given patient:

• Evidence base: Subcutaneous injection has the most established clinical evidence and is the default formulation in most programs.
• Patient preference and tolerability: Needle aversion is a real clinical consideration. For patients who will not use subcutaneous injection, a sublingual or nasal formulation with its caveats acknowledged may be preferable to no treatment.
• Monitoring: IGF-1 levels are commonly used to monitor response to sermorelin. A clinician prescribing an alternative formulation should monitor whether the expected pituitary response is occurring and adjust the protocol accordingly.
• Dosing adjustment: Clinicians who prescribe sublingual or nasal sermorelin often use higher doses to account for expected lower bioavailability, guided by lab monitoring rather than fixed mg-for-mg dose equivalency.

If formulation preference is important to you, raise it explicitly during your clinician intake conversation. A clinician familiar with sermorelin will be able to discuss the tradeoffs candidly.

What to look for in a compounding pharmacy’s sermorelin

Regardless of formulation, sermorelin should be prepared by a licensed 503A compounding pharmacy in the USA. For any formulation:

• The pharmacy should operate under state pharmacy board oversight and be licensed in the state where you reside.
• Sermorelin should be sourced from a documented US API (active pharmaceutical ingredient) supplier — no hidden overseas supply chain.
• For injectable sermorelin, sterility testing and endotoxin testing are standard expectations for a responsible 503A pharmacy.
• The clinician and pharmacy work together — the prescription should specify the formulation, concentration, and administration route explicitly.

Frequently asked questions